Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer.

Layman RM, Ruppert AS, Lynn M, Mrozek E, Ramaswamy B, Lustberg MB, Wesolowski R, Ottman S, Carothers S, Bingman A, Reinbolt R, Kraut EH, Shapiro CL.

Cancer Chemother Pharmacol. 2013 May;71(5):1183-90. doi: 10.1007/s00280-013-2112-2. Epub 2013 Feb 21.

2.

Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.

Messersmith WA, Laheru DA, Senzer NN, Donehower RC, Grouleff P, Rogers T, Kelley SK, Ramies DA, Lum BL, Hidalgo M.

Clin Cancer Res. 2004 Oct 1;10(19):6522-7.

3.

Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial.

Loibl S, Murmann C, Schwedler K, Warm M, Müller L, Heinrich G, Nekljudova V, von Minckwitz G.

Cancer Chemother Pharmacol. 2009 Apr;63(5):953-8. doi: 10.1007/s00280-008-0821-8. Epub 2008 Aug 21.

PMID:
18716777
4.

Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer.

Jiang Y, Mackley HB, Kimchi ET, Zhu J, Gusani N, Kaifi J, Staveley-O'Carroll KF, Belani CP.

Cancer Chemother Pharmacol. 2014 Jul;74(1):205-10. doi: 10.1007/s00280-014-2488-7. Epub 2014 Jun 8.

PMID:
24908435
5.

Pneumocystis jiroveci Pneumonia in an Atypical Host.

Reinbolt RE, Alam S, Layman R, Shapiro C, Lustberg M.

Clin Breast Cancer. 2012 Apr;12(2):138-41. doi: 10.1016/j.clbc.2011.10.003. Epub 2011 Dec 1. No abstract available.

6.

Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer.

Krzakowski M, Bennouna J, Dansin E, Kowalski D, Hiret S, Penel N, Favrel S, Tourani JM.

Cancer Chemother Pharmacol. 2014 Feb;73(2):231-6. doi: 10.1007/s00280-013-2342-3. Epub 2013 Nov 13.

7.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica.

Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26.

PMID:
22285168
8.

Pneumocystis carinii pneumonia as a complication of bendamustine monotherapy in a patient with advanced progressive breast cancer.

Klippstein A, Schneider CP, Sayer HG, Höffken K.

J Cancer Res Clin Oncol. 2003 May;129(5):316-9. Epub 2003 May 17.

PMID:
12756557
9.

Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).

Murakami H, Tamura T, Takahashi T, Nokihara H, Naito T, Nakamura Y, Nishio K, Seki Y, Sarashina A, Shahidi M, Yamamoto N.

Cancer Chemother Pharmacol. 2012 Apr;69(4):891-9. doi: 10.1007/s00280-011-1738-1. Epub 2011 Nov 10.

PMID:
22071596
10.

Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.

Chiorean EG, Ramasubbaiah R, Yu M, Picus J, Bufill JA, Tong Y, Coleman N, Johnston EL, Currie C, Loehrer PJ.

Oncologist. 2012;17(1):13. doi: 10.1634/theoncologist.2011-0253. Epub 2011 Dec 30.

11.

Bendamustine and rituximab in relapsed and refractory hairy cell leukemia.

Burotto M, Stetler-Stevenson M, Arons E, Zhou H, Wilson W, Kreitman RJ.

Clin Cancer Res. 2013 Nov 15;19(22):6313-21. doi: 10.1158/1078-0432.CCR-13-1848. Epub 2013 Oct 4.

12.

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.

Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, Kozloff MF, Clark JI, Yan DH, Liu W, Pierce C, Dancey JE, Stenson K, Blair E, Dekker A, Vokes EE.

Lancet Oncol. 2009 Mar;10(3):247-57. doi: 10.1016/S1470-2045(09)70002-6. Epub 2009 Feb 7.

13.

Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer.

Tsimberidou AM, Adamopoulos AM, Ye Y, Piha-Paul S, Janku F, Fu S, Hong D, Falchook GS, Naing A, Wheler J, Fortier A, Kurzrock R, Hess KR.

J Natl Compr Canc Netw. 2014 Feb;12(2):194-203.

PMID:
24586081
14.

Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.

Tolcher AW, LoRusso P, Arzt J, Busman TA, Lian G, Rudersdorf NS, Vanderwal CA, Kirschbrown W, Holen KD, Rosen LS.

Cancer Chemother Pharmacol. 2015 Nov;76(5):1025-32. doi: 10.1007/s00280-015-2883-8. Epub 2015 Sep 29.

PMID:
26420235
15.

Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.

Weickhardt AJ, Price TJ, Chong G, Gebski V, Pavlakis N, Johns TG, Azad A, Skrinos E, Fluck K, Dobrovic A, Salemi R, Scott AM, Mariadason JM, Tebbutt NC.

J Clin Oncol. 2012 May 1;30(13):1505-12. doi: 10.1200/JCO.2011.38.6599. Epub 2012 Mar 12.

PMID:
22412142
16.

A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.

Van Cutsem E, Verslype C, Beale P, Clarke S, Bugat R, Rakhit A, Fettner SH, Brennscheidt U, Feyereislova A, Delord JP.

Ann Oncol. 2008 Feb;19(2):332-9. Epub 2007 Nov 6.

PMID:
17986625
17.

Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma.

Vacirca JL, Acs PI, Tabbara IA, Rosen PJ, Lee P, Lynam E.

Ann Hematol. 2014 Mar;93(3):403-9. doi: 10.1007/s00277-013-1879-x. Epub 2013 Aug 17.

18.

A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.

Bauman JE, Arias-Pulido H, Lee SJ, Fekrazad MH, Ozawa H, Fertig E, Howard J, Bishop J, Wang H, Olson GT, Spafford MJ, Jones DV, Chung CH.

Oral Oncol. 2013 May;49(5):461-7. doi: 10.1016/j.oraloncology.2012.12.016. Epub 2013 Feb 4.

19.

A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.

Lind JS, Dingemans AM, Groen HJ, Thunnissen FB, Bekers O, Heideman DA, Honeywell RJ, Giovannetti E, Peters GJ, Postmus PE, van Suylen RJ, Smit EF.

Clin Cancer Res. 2010 Jun 1;16(11):3078-87. doi: 10.1158/1078-0432.CCR-09-3033. Epub 2010 Apr 15.

20.

Erlotinib and chemoradiation in patients with surgically resected locally advanced squamous cell carcinoma of the head and neck: a GICOR phase I trial.

Arias de la Vega F, Contreras J, de Las Heras M, de la Torre A, Arrazubi V, Herruzo I, Prieto I, García-Saenz JA, Romero J, Calvo FA; Members of GICOR (Grupo de Investigación Clínica en Oncología Radioterápica) group.

Ann Oncol. 2012 Apr;23(4):1005-9. doi: 10.1093/annonc/mdr315. Epub 2011 Jul 21.

PMID:
21778302

Supplemental Content

Support Center